JASON BACHARACH
- Type
- Physician · Allopathic & Osteopathic Physicians / Ophthalmology / Glaucoma Specialist
- Where
- PETALUMA, CA
- NPI
- 1639160112
- Received
- $1,673,625 in 2,067 records, 2019 to 2025 ($1,655,449 general, $18,176 research)
- As principal investigator
- $748,714 of research payments to others in 292 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 302 | $269,623 |
| 2025 | Research payment | 2 | $2,500 |
| 2024 | General payment | 307 | $241,718 |
| 2023 | General payment | 272 | $252,865 |
| 2023 | Research payment | 1 | $2,800 |
| 2022 | General payment | 312 | $239,632 |
| 2021 | General payment | 270 | $217,356 |
| 2020 | General payment | 232 | $217,996 |
| 2019 | General payment | 366 | $216,257 |
| 2019 | Research payment | 3 | $12,876 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 295 | $704,354 |
| Consulting Fee | 249 | $574,367 |
| Compensation for serving as faculty or as a speaker for a medical education program | 34 | $133,312 |
| Travel and Lodging | 554 | $117,626 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 16 | $44,350 |
| Honoraria | 27 | $40,705 |
| Food and Beverage | 881 | $40,271 |
| Research payment | 6 | $18,176 |
| Long term medical supply or device loan | 1 | $292 |
| Education | 2 | $104 |
| Gift | 2 | $64 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-22 | Tarsus Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-12-18 | Alcon Vision LLC | $5,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-12-18 | Alcon Vision LLC | $131 | Travel and Lodging | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-12-18 | Alcon Vision LLC | $97 | Travel and Lodging | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-12-17 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2025-12-16 | Harrow Eye, LLC | $33 | Food and Beverage | In-kind items and services | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-12-15 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-12-11 | ABBVIE INC. | $2,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2025 | |
| 2025-12-11 | Alcon Vision LLC | $146 | Food and Beverage | In-kind items and services | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-12-11 | Bausch & Lomb Americas Inc. | $9 | Food and Beverage | In-kind items and services | ScoutPro Osmolarity System Device, Ophthalmology | 2025 | |
| 2025-12-09 | SUN PHARMACEUTICAL INDUSTRIES INC. | $11 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-12-04 | Alcon Vision LLC | $5,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-12-04 | Bausch & Lomb Americas Inc. | $5 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-12-02 | Thea Pharma Inc. | $13 | Food and Beverage | In-kind items and services | IYUZEH Drug, OPHTHALMOLOGY | 2025 | |
| 2025-11-26 | Beaver-Visitec International, Inc. | $47 | Food and Beverage (2 payments) | In-kind items and services | 2025 | ||
| 2025-11-25 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2025-11-25 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $6,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $1,266 | Travel and Lodging | In-kind items and services | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $140 | Travel and Lodging | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $123 | Food and Beverage | In-kind items and services | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $112 | Travel and Lodging | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $88 | Travel and Lodging | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $34 | Travel and Lodging | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $33 | Food and Beverage | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $31 | Food and Beverage | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $22 | Food and Beverage | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $19 | Food and Beverage | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $12 | Food and Beverage | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $9 | Travel and Lodging | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-20 | Alcon Vision LLC | $8 | Food and Beverage | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-19 | Glaukos Corporation | $3,825 | Consulting Fee | Cash or cash equivalent | Mitosol Drug, Ophthalmology | 2025 | |
| 2025-11-19 | Glaukos Corporation | $1,700 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-17 | Glaukos Corporation | $34 | Food and Beverage | Cash or cash equivalent | iDoseTR Drug, Ophthalmology | 2025 | |
| 2025-11-17 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-11-11 | SUN PHARMACEUTICAL INDUSTRIES INC. | $16 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-11-07 | ABBVIE INC. | $76 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2025-11-07 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $6,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $6,000 | Consulting Fee | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $1,000 | Consulting Fee | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $1,000 | Consulting Fee | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $346 | Travel and Lodging | In-kind items and services | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $330 | Travel and Lodging | In-kind items and services | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $328 | Travel and Lodging | In-kind items and services | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $119 | Food and Beverage | In-kind items and services | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $40 | Travel and Lodging | Cash or cash equivalent | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $38 | Travel and Lodging | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $26 | Travel and Lodging | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $26 | Travel and Lodging | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $24 | Travel and Lodging | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $23 | Food and Beverage | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $22 | Food and Beverage | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $21 | Travel and Lodging | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Alcon Vision LLC | $14 | Travel and Lodging | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-11-05 | Bausch & Lomb Americas Inc. | $6,800 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-11-05 | Bausch & Lomb Americas Inc. | $850 | Consulting Fee | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-11-03 | ABBVIE INC. | $1,050 | Consulting Fee | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-11-01 | Bausch & Lomb Americas Inc. | $8,500 | Consulting Fee | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-10-30 | Alcon Vision LLC | $418 | Travel and Lodging | In-kind items and services | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-10-30 | Alcon Vision LLC | $200 | Travel and Lodging | In-kind items and services | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-10-30 | Alcon Vision LLC | $120 | Food and Beverage | In-kind items and services | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-10-29 | Harrow Eye, LLC | $19 | Food and Beverage | In-kind items and services | VEVYE Drug, OPTOMETRY | 2025 | |
| 2025-10-27 | Alcon Vision LLC | $123 | Food and Beverage | In-kind items and services | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-10-23 | Alcon Vision LLC | $6,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-10-23 | Kowa Pharmaceuticals America, Inc. | $1,125 | Honoraria | Cash or cash equivalent | 2025 | ||
| 2025-10-23 | Alcon Vision LLC | $49 | Travel and Lodging | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-10-23 | Alcon Vision LLC | $8 | Travel and Lodging | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-10-22 | ABBVIE INC. | $700 | Consulting Fee | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-10-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-10-20 | Bausch & Lomb Americas Inc. | $307 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-10-20 | Bausch & Lomb Americas Inc. | $220 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-10-20 | Bausch & Lomb Americas Inc. | $208 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-10-20 | Bausch & Lomb Americas Inc. | $197 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-10-20 | Bausch & Lomb Americas Inc. | $115 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-10-20 | Bausch & Lomb Americas Inc. | $52 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-10-17 | Bausch & Lomb Americas Inc. | $1,700 | Consulting Fee | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-17 | Alcon Vision LLC | $89 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-17 | Bausch & Lomb Americas Inc. | $70 | Consulting Fee | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-17 | Harrow Eye, LLC | $51 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-17 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-10-16 | Alcon Vision LLC | $121 | Food and Beverage | In-kind items and services | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-10-15 | Bausch & Lomb Americas Inc. | $1,700 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-15 | Thea Pharma Inc. | $5 | Food and Beverage | In-kind items and services | IYUZEH Drug, OPHTHALMOLOGY | 2025 | |
| 2025-10-10 | ABBVIE INC. | $1,050 | Consulting Fee | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-10-08 | Bausch & Lomb Americas Inc. | $5,550 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-10-08 | Glaukos Corporation | $2,550 | Consulting Fee | Cash or cash equivalent | Travoprost Intraocular Implant - iDose Drug, Ophthalmology | 2025 | |
| 2025-10-07 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-10-03 | ABBVIE INC. | $1,050 | Consulting Fee | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-10-03 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-10-01 | Bausch & Lomb Americas Inc. | $6,800 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-26 | Bausch & Lomb Americas Inc. | $14 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-25 | Bausch & Lomb Americas Inc. | $352 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-25 | Bausch & Lomb Americas Inc. | $281 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-25 | Bausch & Lomb Americas Inc. | $124 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-25 | Bausch & Lomb Americas Inc. | $56 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-25 | Bausch & Lomb Americas Inc. | $38 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-25 | Bausch & Lomb Americas Inc. | $25 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-25 | Bausch & Lomb Americas Inc. | $25 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-25 | Bausch & Lomb Americas Inc. | $10 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-25 | Bausch & Lomb Americas Inc. | $9 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-23 | Alcon Vision LLC | $24 | Food and Beverage | In-kind items and services | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $99 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $80 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $78 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $56 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $39 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $20 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $17 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $12 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $12 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-20 | Bausch & Lomb Americas Inc. | $12 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-19 | Bausch & Lomb Americas Inc. | $442 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-19 | Bausch & Lomb Americas Inc. | $336 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-19 | Bausch & Lomb Americas Inc. | $74 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-19 | Bausch & Lomb Americas Inc. | $32 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-19 | Bausch & Lomb Americas Inc. | $28 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-19 | Bausch & Lomb Americas Inc. | $15 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-19 | Bausch & Lomb Americas Inc. | $9 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-09-18 | Sight Sciences, Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2025 | |
| 2025-09-17 | Glaukos Corporation | $2,550 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-16 | ABBVIE INC. | $7,612 | Consulting Fee | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-09-15 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-09-11 | ABBVIE INC. | $1,812 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-05 | Alcon Vision LLC | $18 | Food and Beverage | In-kind items and services | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-29 | Bausch & Lomb Americas Inc. | $8,500 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-26 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-08-21 | Alcon Vision LLC | $1,000 | Consulting Fee | Cash or cash equivalent | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-08-19 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2025-08-15 | Bausch & Lomb Americas Inc. | $23 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-08-14 | ABBVIE INC. | $2,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2025 | |
| 2025-08-14 | Alcon Vision LLC | $14 | Food and Beverage | In-kind items and services | TRYPTYR Drug, Ophthalmology | 2025 | |
| 2025-08-11 | Bausch & Lomb Americas Inc. | $1,700 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $99 | Travel and Lodging | Cash or cash equivalent | Cequa Drug, Ophthalmology | 2025 | |
| 2025-08-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $97 | Travel and Lodging | Cash or cash equivalent | Cequa Drug, Ophthalmology | 2025 | |
| 2025-08-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $97 | Travel and Lodging | Cash or cash equivalent | Cequa Drug, Ophthalmology | 2025 | |
| 2025-08-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $35 | Food and Beverage | Cash or cash equivalent | Cequa Drug, Ophthalmology | 2025 | |
| 2025-08-07 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-08-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $14 | Travel and Lodging | Cash or cash equivalent | Cequa Drug, Ophthalmology | 2025 | |
| 2025-08-06 | Thea Pharma Inc. | $15 | Food and Beverage | In-kind items and services | IYUZEH Drug, OPHTHALMOLOGY | 2025 | |
| 2025-07-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,235 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Cequa Drug, Ophthalmology | 2025 | |
| 2025-07-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | $712 | Travel and Lodging | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-07-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | $123 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-07-30 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2025-07-28 | Bausch & Lomb Americas Inc. | $20 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-07-24 | Harrow Eye, LLC | $9 | Food and Beverage | In-kind items and services | IHEEZO Drug, OPTOMETRY | 2025 | |
| 2025-07-22 | SUN PHARMACEUTICAL INDUSTRIES INC. | $66 | Travel and Lodging | Cash or cash equivalent | Cequa Drug, Ophthalmology | 2025 | |
| 2025-07-22 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8 | Travel and Lodging | Cash or cash equivalent | Cequa Drug, Ophthalmology | 2025 | |
| 2025-07-11 | SUN PHARMACEUTICAL INDUSTRIES INC. | $266 | Travel and Lodging | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-07-10 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,775 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Cequa Drug, Ophthalmology | 2025 | |
| 2025-07-10 | Alcon Vision LLC | $5,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-07-10 | Bausch & Lomb Americas Inc. | $637 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-07-10 | SUN PHARMACEUTICAL INDUSTRIES INC. | $397 | Travel and Lodging | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-07-10 | SUN PHARMACEUTICAL INDUSTRIES INC. | $215 | Travel and Lodging | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-07-10 | SUN PHARMACEUTICAL INDUSTRIES INC. | $119 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-07-10 | Bausch & Lomb Americas Inc. | $5 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-07-10 | Bausch & Lomb Americas Inc. | $4 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-07-10 | Bausch & Lomb Americas Inc. | $4 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-07-10 | Bausch & Lomb Americas Inc. | $2 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-07-03 | Sight Sciences, Inc. | $1,500 | Research payment | Cash or cash equivalent | OMNI SURGICAL SYSTEM Device, Ophthalmology | A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX) | 2025 |
| 2025-07-01 | Dompe US, Inc. | $31 | Food and Beverage | In-kind items and services | OXERVATE Drug, SOLUTION/ DROPS | 2025 | |
| 2025-06-30 | Ocular Therapeutix, Inc. | $1,000 | Research payment | Cash or cash equivalent | A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC | 2025 | |
| 2025-06-30 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-06-26 | Alcon Vision LLC | $1,188 | Travel and Lodging | In-kind items and services | Rhopressa Drug, Ophthalmology | 2025 | |
| 2025-06-26 | ABBVIE INC. | $400 | Consulting Fee | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-06-26 | ABBVIE INC. | $400 | Consulting Fee | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-06-26 | ABBVIE INC. | $300 | Consulting Fee | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-06-26 | Alcon Vision LLC | $125 | Food and Beverage | In-kind items and services | Rocklatan Drug, Ophthalmology | 2025 | |
| 2025-06-26 | Bausch & Lomb Americas Inc. | $15 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-06-23 | Bausch & Lomb Americas Inc. | $6,800 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-06-23 | Bausch & Lomb Americas Inc. | $6,800 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-06-23 | Bausch & Lomb Americas Inc. | $22 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-06-20 | ABBVIE INC. | $400 | Consulting Fee | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-06-20 | ABBVIE INC. | $300 | Consulting Fee | Cash or cash equivalent | DURYSTA Drug, EYE CARE | 2025 | |
| 2025-06-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,465 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Cequa Drug, Ophthalmology | 2025 | |
| 2025-06-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | $121 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2025 | |
| 2025-06-18 | Sight Sciences, Inc. | $19 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2025 | |
| 2025-06-16 | Bausch & Lomb Americas Inc. | $6,800 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-06-12 | Bausch & Lomb Americas Inc. | $17,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-12 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,800 | Consulting Fee | Cash or cash equivalent | Cequa Drug, Ophthalmology | 2025 | |
| 2025-06-06 | Bausch & Lomb Americas Inc. | $342 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-06-06 | Bausch & Lomb Americas Inc. | $182 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-06-06 | Bausch & Lomb Americas Inc. | $124 | Food and Beverage | In-kind items and services | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-06-06 | Bausch & Lomb Americas Inc. | $80 | Travel and Lodging | Cash or cash equivalent | MIEBO Drug, Ophthalmology | 2025 | |
| 2025-06-05 | Bausch & Lomb Americas Inc. | $853 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-06-05 | Bausch & Lomb Americas Inc. | $342 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-06-05 | Bausch & Lomb Americas Inc. | $266 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-06-05 | Bausch & Lomb Americas Inc. | $239 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-06-05 | Bausch & Lomb Americas Inc. | $121 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-06-05 | Bausch & Lomb Americas Inc. | $119 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-06-05 | Bausch & Lomb Americas Inc. | $66 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-05-31 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2025-05-30 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2025-05-29 | ABBVIE INC. | $725 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-29 | Bausch & Lomb Americas Inc. | $284 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-05-29 | Bausch & Lomb Americas Inc. | $251 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-05-29 | Bausch & Lomb Americas Inc. | $122 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-05-29 | Bausch & Lomb Americas Inc. | $50 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-05-29 | Bausch & Lomb Americas Inc. | $46 | Travel and Lodging | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 |
The latest 200 records of 2,067.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-05 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $10,093 | A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo App | 2025 |
| 2025-10-15 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $6,849 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-10-15 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $3,267 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-10-09 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $221 | A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo App | 2025 |
| 2025-08-14 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $5,142 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-08-14 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $3,072 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-06-13 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $5,245 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-04-28 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $4,609 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-04-28 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $3,407 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-04-03 | Sight Sciences, Inc. | North Bay Eye Associates Inc. | $3,000 | A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Gl | 2025 |
| 2025-03-19 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $4,156 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-02-12 | Glaukos Corporation | North Bay Eye Associates | $513 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2025 |
| 2025-02-10 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $3,299 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-01-17 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $9,167 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2024-12-31 | Ocular Therapeutix, Inc. | North Bay Eye Associates, Inc. | $16,803 | A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC | 2024 |
| 2024-11-22 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $13,354 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2024 |
| 2024-10-10 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $24,168 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2024 |
| 2024-09-19 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $300 | 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) | 2024 |
| 2024-09-19 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $720 | 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) | 2024 |
| 2024-09-19 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $300 | 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) | 2024 |
| 2024-09-19 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $720 | 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) | 2024 |
| 2024-07-19 | Oyster Point Pharma, Inc. | North Bay Eye Associates | $1,500 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2024 |
| 2024-04-03 | Glaukos Corporation | North Bay Eye Associates | $672 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2024 |
| 2024-01-10 | Glaukos Corporation | North Bay Eye Associates | $402 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2024 |
| 2023-12-31 | Ocular Therapeutix, Inc. | North Bay Eye Associates, Inc. | $14,384 | A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC | 2023 |
| 2023-12-31 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $762 | Long-term Safety and Efficacy Extension Trial of Bimatoprost SR | 2023 |
| 2023-12-06 | Glaukos Corporation | North Bay Eye Associates | $672 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-11-21 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $6,000 | Long-term Safety and Efficacy Extension Trial of Bimatoprost SR | 2023 |
| 2023-11-16 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $6,000 | Long-term Safety and Efficacy Extension Trial of Bimatoprost SR | 2023 |
| 2023-10-11 | Glaukos Corporation | North Bay Eye Associates | $606 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-10-04 | Glaukos Corporation | Clinigen Clinical Supplies Management | $470 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-09-06 | Glaukos Corporation | InComm Digital Solutions, LLC | $231 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-08-16 | Glaukos Corporation | Clinigen Clinical Supplies Management | $191 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-07-05 | Glaukos Corporation | North Bay Eye Associates | $1,596 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-07-03 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $446 | 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) (ARGOS) | 2023 |
| 2023-06-28 | Glaukos Corporation | Clinigen Clinical Supplies Management | $594 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-06-02 | Alcon Research LLC | NORTH BAY EYE ASSOCIATES INC | $3,750 | A MULTICENTER, OPEN-LABEL ROCKLATAN EVALUATION OF IOP LOWERING EFFICACY AND SAFETY AS REPLACEMENT OF CURRENT MEDICAL THE | 2023 |
| 2023-04-28 | Glaukos Corporation | North Bay Eye Associates | $606 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-03-29 | Amneal Pharmaceuticals LLC | NORTH BAY EYE ASSOCIATES INC | $3,915 | BIMATOPROST | 2023 |
| 2023-03-29 | Glaukos Corporation | Clinigen Clinical Supplies Management | $345 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-03-29 | Amneal Pharmaceuticals LLC | NORTH BAY EYE ASSOCIATES INC | $3,915 | BIMATOPROST | 2023 |
| 2023-03-29 | Amneal Pharmaceuticals LLC | NORTH BAY EYE ASSOCIATES INC | $3,915 | BIMATOPROST | 2023 |
| 2023-03-10 | Alcon Research LLC | NORTH BAY EYE ASSOCIATES INC | $2,500 | A MULTICENTER, OPEN-LABEL ROCKLATAN EVALUATION OF IOP LOWERING EFFICACY AND SAFETY AS REPLACEMENT OF CURRENT MEDICAL THE | 2023 |
| 2023-03-01 | Glaukos Corporation | North Bay Eye Associates | $1,074 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-03-01 | Amneal Pharmaceuticals LLC | Houston Eye Associates | $114 | BIMATOPROST | 2023 |
| 2023-03-01 | Amneal Pharmaceuticals LLC | NORTH BAY EYE ASSOCIATES INC | $114 | BIMATOPROST | 2023 |
| 2023-03-01 | Amneal Pharmaceuticals LLC | NORTH BAY EYE ASSOCIATES INC | $114 | BIMATOPROST | 2023 |
| 2023-03-01 | Amneal Pharmaceuticals LLC | NORTH BAY EYE ASSOCIATES INC | $114 | BIMATOPROST | 2023 |
| 2023-02-15 | Glaukos Corporation | Clinigen Clinical Supplies Management | $233 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-02-02 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $163 | 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) (ARGOS) | 2023 |
| 2023-02-01 | Glaukos Corporation | North Bay Eye Associates | $1,500 | Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effic | 2023 |
| 2023-02-01 | Glaukos Corporation | North Bay Eye Associates | $1,500 | Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effic | 2023 |
| 2023-02-01 | Glaukos Corporation | North Bay Eye Associates | $402 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-02-01 | Alcon Research LLC | NORTH BAY EYE ASSOCIATES INC | $3,765 | A MULTICENTER, OPEN-LABEL ROCKLATAN EVALUATION OF IOP LOWERING EFFICACY AND SAFETY AS REPLACEMENT OF CURRENT MEDICAL THE | 2023 |
| 2022-12-31 | Ocular Therapeutix, Inc. | North Bay Eye Associates, Inc. | $3,250 | A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC | 2022 |
| 2022-12-31 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $359 | Long-term Safety and Efficacy Extension Trial of Bimatoprost SR | 2022 |
| 2022-12-07 | Glaukos Corporation | North Bay Eye Associates | $1,800 | 2022 | |
| 2022-11-04 | Alcon Research LLC | North Bay Eye Associates, Inc. | $6,245 | A MULTICENTER, OPEN-LABEL ROCKLATAN (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% EVALUATION OF IOP LOWERING | 2022 |
| 2022-10-26 | Glaukos Corporation | Clinigen Clinical Supplies Management | $376 | 2022 | |
| 2022-10-26 | Glaukos Corporation | North Bay Eye Associates | $1,018 | 2022 | |
| 2022-10-26 | Glaukos Corporation | Clinigen Clinical Supplies Management | $376 | 2022 | |
| 2022-10-13 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $626 | 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) | 2022 |
| 2022-09-14 | Glaukos Corporation | SRN CLINICAL SCIENCE INC. | $630 | 2022 | |
| 2022-09-07 | Glaukos Corporation | North Bay Eye Associates | $1,410 | 2022 | |
| 2022-09-07 | Glaukos Corporation | North Bay Eye Associates | $7,296 | 2022 | |
| 2022-08-17 | ABBVIE INC. | NORTH BAY EYE ASSOCIATES INC | $1,055 | 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) | 2022 |
| 2022-08-02 | Glaukos Corporation | Clinigen Clinical Supplies Management | $333 | 2022 | |
| 2022-08-02 | Glaukos Corporation | Clinigen Clinical Supplies Management | $333 | 2022 | |
| 2022-08-02 | Glaukos Corporation | North Bay Eye Associates | $5,438 | 2022 | |
| 2022-08-02 | Glaukos Corporation | North Bay Eye Associates | $4,636 | 2022 | |
| 2022-07-20 | Glaukos Corporation | Konan Medical, USA, Inc. | $463 | 2022 | |
| 2022-07-14 | Alcon Research LLC | North Bay Eye Associates, Inc. | $885 | A MULTICENTER, OPEN-LABEL ROCKLATAN (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% EVALUATION OF IOP LOWERING | 2022 |
| 2022-07-06 | Glaukos Corporation | Clinigen Clinical Supplies Management | $165 | 2022 | |
| 2022-07-06 | Glaukos Corporation | Clinigen Clinical Supplies Management | $165 | 2022 | |
| 2022-07-06 | Glaukos Corporation | North Bay Eye Associates | $8,434 | 2022 | |
| 2022-06-13 | Glaukos Corporation | North Bay Eye Associates | $1,450 | 2022 | |
| 2022-06-07 | Alcon Research LLC | North Bay Eye Associates, Inc. | $16,347 | A MULTICENTER, OPEN-LABEL ROCKLATAN (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% EVALUATION OF IOP LOWERING | 2022 |
| 2022-06-02 | Glaukos Corporation | M&S TECHNOLOGIES | $2,564 | 2022 | |
| 2022-06-02 | Glaukos Corporation | North Bay Eye Associates | $1,008 | 2022 | |
| 2022-05-03 | Glaukos Corporation | North Bay Eye Associates | $792 | 2022 | |
| 2022-05-03 | Glaukos Corporation | North Bay Eye Associates | $2,000 | 2022 | |
| 2022-05-03 | Glaukos Corporation | North Bay Eye Associates | $2,000 | 2022 | |
| 2022-04-27 | Glaukos Corporation | Clinigen Clinical Supplies Management | $362 | 2022 | |
| 2022-04-27 | Glaukos Corporation | Clinigen Clinical Supplies Management | $362 | 2022 | |
| 2022-04-06 | Glaukos Corporation | Clinigen Clinical Supplies Management | $7 | 2022 | |
| 2022-04-06 | Glaukos Corporation | Clinigen Clinical Supplies Management | $7 | 2022 | |
| 2022-03-29 | Glaukos Corporation | M&S TECHNOLOGIES | $4,106 | 2022 | |
| 2022-03-28 | Padagis US LLC | North Bay Eye Associates, Inc. | $4,140 | Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Brimo | 2022 |
| 2022-03-16 | Glaukos Corporation | Amazon.com, Inc. | $1 | 2022 | |
| 2022-03-16 | Glaukos Corporation | Clinigen Clinical Supplies Management | $834 | 2022 | |
| 2022-03-16 | Glaukos Corporation | Clinigen Clinical Supplies Management | $834 | 2022 | |
| 2022-03-09 | Glaukos Corporation | Precision Vision | $1,313 | 2022 | |
| 2022-03-09 | Glaukos Corporation | Precision Vision | $755 | 2022 | |
| 2022-03-09 | Allergan, Inc. | NORTH BAY EYE ASSOCIATESINC(NBEA) | $3,767 | 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) | 2022 |
| 2022-03-09 | Glaukos Corporation | NEUROPTICS, INC. | $341 | 2022 | |
| 2022-03-04 | Glaukos Corporation | North Bay Eye Associates | $1,866 | 2022 | |
| 2022-02-24 | Padagis US LLC | North Bay Eye Associates, Inc. | $19,530 | Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Brimo | 2022 |
| 2022-02-16 | Glaukos Corporation | Precision Vision | $258 | 2022 | |
| 2022-02-16 | Glaukos Corporation | Amazon.com, Inc. | $45 | 2022 | |
| 2022-02-15 | Padagis US LLC | North Bay Eye Associates, Inc. | $15,706 | Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Brimo | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Petaluma, CA, county Sonoma County, CA, state California; placed by its city name.
| Measure | Place (city or town) Petaluma, CA | County Sonoma County, CA | State California |
|---|---|---|---|
| Population B01003 | 59,247 | 485,040 | 39,287,377 |
| Population, 2020 census P1 | 59,776 | 488,863 | 39,538,223 |
| Median age B01002 | 45.3 | 42.9 | 37.9 |
| Under 18 B01001 | 18.2% | 19.0% | 22.0% |
| 65 and over B01001 | 22.1% | 21.5% | 15.7% |
| Households B11001 | 24,239 | 190,998 | 13,548,091 |
| Foreign born B05002 | 15.3% | 16.8% | 27.0% |
| Median household income B19013 | $115,430 | $104,674 | $99,122 |
| Median family income B19113 | $141,576 | $126,900 | $113,346 |
| Per capita income B19301 | $60,931 | $56,640 | $49,513 |
| Poverty rate B17001 | 6.5% | 8.9% | 12.0% |
| Unemployment rate B23025 | 4.6% | 5.7% | 6.6% |
| Civilian labor force B23025 | 32,005 | 258,155 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.7 | 25.1 | 28.7 |
| Bachelor's degree or higher B15003 | 43.8% | 38.5% | 37.1% |
| Housing units B25001 | 25,107 | 207,699 | 14,644,735 |
| Owner-occupied B25003 | 64.5% | 62.6% | 55.9% |
| Renters B25003 | 35.5% | 37.4% | 44.1% |
| Median home value B25077 | $878,600 | $815,500 | $734,700 |
| Median gross rent B25064 | $2,440 | $2,158 | $2,036 |
| White, not Hispanic B03002 | 66.8% | 57.9% | 33.8% |
| Black B03002 | 1.2% | 1.5% | 5.2% |
| Hispanic or Latino B03002 | 21.7% | 30.0% | 40.2% |
| Asian B03002 | 3.7% | 4.3% | 15.3% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Petaluma, CA.
Comments